Verve Therapeutics/VERV

$15.84

-2.76%
-
1D1W1MYTD1YMAX

About Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second product candidate VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a regulator of cholesterol and triglyceride metabolism.

Ticker

VERV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sekar Kathiresan

Employees

255

Headquarters

Boston, United States

VERV Metrics

BasicAdvanced
$1.36B
Market cap
-
P/E ratio
-$3.10
EPS
-
Beta
-
Dividend rate

What the Analysts think about VERV

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 7 analysts.
226.45% upside
High $75.00
Low $30.00
$15.84
Current price
$51.71
Average price target

VERV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-947.05% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.1M
64.52%
Net income
$-48.3M
5.69%
Profit margin
-947.05%
-35.76%

VERV Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.06%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.84
-$0.87
-$0.72
-$0.69
-
Expected
-$0.78
-$0.92
-$0.92
-$0.82
-$0.73
Surprise
7.83%
-5.23%
-21.57%
-16.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Verve Therapeutics stock

Buy or sell Verve Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing